Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.
The drug likely wouldn't be approved in the U.S. before 2019, however.
Wall Street futures are edging higher amid a "Super Thursday" of corporate earnings that will culminate with Apple's much-anticipated quarterly update and the first official indication on sales of its flagship iPhone X.
Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.
After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.